Share your videos with the world

Sign Up | Log In | Help  

   
 
Related Tags: health  cancer  breast  treatment  screening  technology  jill  connick  recovery  multivu  8280451  science  women  lls  leukemia  lymphoma  equal  cancer  research  stem  multivu  8128552  woman  health  comfort  replens  gel  dryness  vaginal  menopause  multivu  8066251  health  medicine  pharmaceuticals  gw  manufacturing  drugs  epileptic  treatment  pills  multivu  8109951  usahs  health  rehabilitative  sciences  education  school  research  students  weight  treatments  multivu  7743851  technologytm  health  sciences  usana  healthcare  nutrition  cells  wellness  body  multivu  7736551  science  technology  health  medical  award  biologist  yoshinori  ohsumi  research  cure  multivu  7856351  cutanea  life  sciences  technology  dermatologists  health  skin  disorders  doctors  skin  care  multivu  7743651  plane  aurora  flight  sciences  aircraft  technology  lightningstrike  vtol  xplane  darpa  vertical  multivu  7617851  edwards  lifesciences  cardiovascular  medicine  research  artificial  heart  valves  health  science  award  multivu  7536851  iluvien  alimera  sciences  diabetic  macular  edema  dme  diabetes  eyesight  vision  eye  care  treatment  multivu  7496251  astellas  innovation  debate  2015  digital  hospital  personalised  medicine  health  healthcare  multivu  7432051 
Search // sciences
Results 1-12 of 35 for ' sciences ' (2 seconds)
Grammy and Emmy award winner, and Tony award nominee, the multi-talented musician, singer and actor Harry Connick, Jr. and his wife of 24 years and former model, Jill Connick, recently marked the fifth anniversary of Jill’s recovery from breast cancer. As Jill credits timely screening and early detection for being a cancer survivor today, she is joining Harry to share their experience and to raise awareness of another cancer for which timely screening is critical: colon cancer.* Their efforts will support The New 50, a public education campaign sponsored by Exact Sciences, that debuts today during Colorectal Cancer Awareness Month. The initiative aims to encourage people 50 and older to talk with their healthcare provider about screening, including the modern, noninvasive options that can fit into any schedule of this busy, on-the-go “new 50” generation. To view the multimedia release go to: https://www.multivu.com/players/English/8280451-harry-and-jill-connick-colon-cancer-screening-the-new-50/
Categories // Miscellaneous 
Added: 92 days ago by MultiVuVideos
Runtime: 6m37s | Views: 5 | Comments: 4
Not yet rated
 

 

 

As breakthroughs in cancer treatments are occurring at an ever increasing rate, The Leukemia & Lymphoma Society (LLS) is shining a spotlight on the women in science who are helping to lead these advances. Through its significant investment in cancer research – more than $1.2 billion since its founding nearly 70 years ago – LLS is committed to funding and recognizing female scientists, physicians, social workers and nurses, and encouraging young women to participate in STEM (science, technology, engineering and math) education and pursue careers in the sciences. To view the multimedia release go to: https://www.multivu.com/players/English/8128552-lls-women-in-science/
Categories // Miscellaneous 
Added: 98 days ago by MultiVuVideos
Runtime: 0m45s | Views: 5 | Comments: 4
Not yet rated
 

 

 

The complete solution to managing vaginal dryness and discomfort inside and out is now available to the millions of women changing physically, emotionally and hormonally every day. The maker of #1 doctor recommended Replens™ vaginal moisturizer introduces hormone-free and fragrance-free Replens™ Moisture Restore External Comfort Gel, for soothing relief from external vaginal dryness, in menopause, post-partum, and after a cancer diagnosis. “Ladies, don’t despair. Vaginal dryness can be a nuisance at any age. It’s one of the most common symptoms of menopause and unfortunately, can worsen over time. Luckily, there are non-hormonal products like Replens,” says Mary Jane Minkin, M.D., Clinical Professor of Obstetrics, Gynecology and Reproductive Sciences at Yale University. “I recommend these products to patients as first line therapies to help relieve internal and external vaginal dryness.” To view the multimedia release go to: https://www.multivu.com/players/English/8066251-replens-vaginal-moisture-restore-external-comfort-gel/
Categories // Miscellaneous 
Added: 308 days ago by MultiVuVideos
Runtime: 0m52s | Views: 2 | Comments: 1
Not yet rated
 

 

 

University of St. Augustine for Health Sciences (USAHS), a leading graduate institution that emphasizes health and rehabilitative sciences education through innovative classroom education, is pleased to announce the installation of SafeGait 360° Balance and Mobility Trainer® on its Austin, Texas campus. The device, which was designed in collaboration with experts in physical therapy (PT) and occupational therapy (OT), works to mitigate the risk of injury from falls, protecting both the patient and therapist. In addition, SafeGait 360°’s dynamic fall protection (DFP) distinguishes between a patient’s intentional downward movement and when a patient is actually falling, which allows therapists to easily modify fall protection sensitivity to accommodate and challenge patients at varying stages of independence. USAHS is one of the first higher education institutions in the nation to install this innovative body-weight support and fall protection system. In addition to conducting ground breaking research with patients and students, faculty members with extensive experience in body-weight treatments aim to open a clinic which will provide new treatment options to patients in the Austin community, and will begin seeing patients in October of this year. To view the multimedia release go to: http://www.multivu.com/players/English/7743851-usahs-safegait-360-physical-therapy/
Categories // Miscellaneous 
Added: 628 days ago by MultiVuVideos
Runtime: 1m2s | Views: 79 | Comments: 0
Not yet rated
 

 

 

USANA Health Sciences is pleased to announce an innovative technological advancement: its U.S. patent-pending USANA InCelligence Technology™. This exclusive cell-signaling technology—now found in various USANA® products—is designed to help your body’s cells renew and protect themselves in unique and powerful ways, representing a monumental leap forward in cellular nutrition and overall wellness.* “USANA continues to build a reputation as an innovator in the science of cellular health and nutritional supplementation,” says USANA Founder Dr. Myron Wentz. “With USANA’s InCelligence Technology, we are ensuring that our company remains on the cutting-edge of nutritional supplementation.” To view the multimedia release go to: http://www.multivu.com/players/English/7736551-usana-incelligence-technology/
Categories // Miscellaneous 
Added: 662 days ago by MultiVuVideos
Runtime: 1m4s | Views: 118 | Comments: 0
Not yet rated
 

 

 

As part of an ongoing commitment to support life sciences innovators and the development of integrated, cross-sector solutions to prevent, intercept and cure diseases, Johnson & Johnson today named cell biologist Yoshinori Ohsumi, Ph.D., of the Tokyo Institute of Technology the winner of the 2016 Dr. Paul Janssen Award for Biomedical Research for his pioneering discoveries concerning the molecular basis of autophagy. Dr. Ohsumi was honored today during an event at the 2016 BIO International Convention in San Francisco. A video of his acceptance comments can be viewed here. “Dr. Ohsumi’s curiosity led him to become the first person in the world to determine the molecular mechanism and regulation of autophagy, shedding light on one of the most basic functions of all living cells,” said Paul Stoffels, M.D., Chief Scientific Officer, Johnson & Johnson. “Dr. Ohsumi’s discoveries hold promise for better understanding, preventing and treating many diseases. It is with great pleasure that we celebrate his contributions, which remind us of the innovative spirit Dr. Paul brought to the lab every day.” To view the multimedia release go to: http://www.multivu.com/players/English/7856351-2016-dr-paul-janssen-award-ohsumi/
Categories // Miscellaneous 
Added: 740 days ago by MultiVuVideos
Runtime: 1m37s | Views: 220 | Comments: 0
Not yet rated
 

 

 

Cutanea Life Sciences, Inc. (CLS), an emerging U.S. prescription product development company, formally unveiled its new digital presence, www.cutanea.com, to the dermatology community in conjunction with this winter’s annual gathering of dermatologists from the U.S and around the world. CLS has a stream of innovative product candidates in different stages of development that cover an array of skin conditions, including acne, rosacea, psoriasis and warts caused by human papillomavirus (HPV). CLS’s new digital presence demonstrates the company’s intent to change the way that customers think about a valued dermatology partner. CLS believes that it can make an impact in the current state of dermatology practice through its commitment to focus on unmet and underserved patient needs. In turn this will help medical professionals optimize their practice time through CLS products and services. To view the multimedia release go to: http://www.multivu.com/players/English/7743651-cutanea-life-sciences-dermatology/
Categories // Miscellaneous 
Added: 834 days ago by MultiVuVideos
Runtime: 1m44s | Views: 160 | Comments: 0
Not yet rated
 

 

 

Aurora Flight Sciences announced today that the Defense Advanced Research Projects Agency (DARPA) has awarded the company the prime contract for Phase 2 of the Agency’s Vertical Takeoff and Landing Experimental Plane (VTOL X-Plane) program. VTOL X-Plane seeks to develop a technology demonstrator that could: • Achieve a top sustained flight speed of 300 kt-400 kt • Raise aircraft hover efficiency from 60 percent to at least 75 percent • Present a more favorable cruise lift-to-drag ratio of at least 10, up from 5-6 • Carry a useful load of at least 40 percent of the vehicle’s projected gross weight of 10,000-12,000 pounds The Aurora team’s design for its unmanned aircraft, named LightningStrike, seeks to provide an approximately 50-percent increase in speed over existing VTOL aircraft designed for comparable mission applications. To view the multimedia release go to: http://www.multivu.com/players/English/7617851-aurora-flight-sciences-vtol-xplane-darpa/
Categories // Miscellaneous 
Added: 837 days ago by MultiVuVideos
Runtime: 1m49s | Views: 178 | Comments: 0
Not yet rated
 

 

 

Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that many retina specialists throughout the U.S. are now using ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg to treat patients with diabetic macular edema (DME). The first injections of ILUVIEN in the U.S. were captured during a live web event attended by more than 250 eye care professionals. ILUVIEN is the first multiyear eye implant designed to deliver a continuous, submicrogram daily dose of steroid to the retina for 36 months with one injection. ILUVIEN is indicated for the treatment of DME in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP). To view the Multimedia News Release, go to http://www.multivu.com/players/English/7496251-iluvien-dme/
Added: 1155 days ago by MultiVuVideos
Runtime: 3m35s | Views: 257 | Comments: 1
Not yet rated
 

 

 

Professor Lionel Tarassenko, CBE, Head of Engineering at the University of Oxford and Fellow of the Royal Academy of Engineering and the Academy of Medical Sciences, has joined a panel of internationally recognised experts for the 3rd Astellas Innovation Debate: i-Genes – What the DNA and Data Revolutions mean for our Health, taking place on Thursday 29th January 2015 at the Royal Institution of Great Britain. As the worlds of science and technology come together, the 2015 Astellas Innovation Debate, organised and funded by Astellas, will discuss recent breakthroughs in genetic medicine and smart technology, and what they mean for our health. To view the Multimedia News Release, go to http://www.multivu.com/players/English/7432051-lionel-tarassenko-astellas-debate/
Categories // Science and Technology 
Added: 1237 days ago by MultiVuVideos
Runtime: 2m5s | Views: 264 | Comments: 1
Not yet rated
 

 

 

George Freeman MP, the Minister for Life Sciences, will give the keynote address at the 3rd Astellas Innovation Debate: i-Genes – What the DNA and Data Revolutions mean for our Health, taking place on Thursday 29th January 2015 at the Royal Institution of Great Britain. Organised and funded by Astellas, a progressive pharmaceutical company that explores the frontiers of scientific discovery to translate new knowledge into innovative, reliable medicines, the Astellas Innovation Debates are a series of annual events that bring together some of the world’s most progressive thinkers to discuss the role of innovation in solving some of the greatest challenges of our time. George Freeman’s keynote address will outline the Government’s aim to develop, assess and adopt new drugs, devices and diagnostics as we move towards 21st century, personalised healthcare. To view the Multimedia News Release, go to http://www.multivu.com/players/English/7423951-george-freeman-astellas-debate/
Added: 1246 days ago by MultiVuVideos
Runtime: 3m0s | Views: 325 | Comments: 2
Not yet rated
 

 

 

Phenogen Sciences, Inc. today announced the availability of BREVAGenplus, an easy-to-use predictive risk test for the millions of women at risk of developing sporadic, or non-hereditary, breast cancer. The test is an enhancement of the company’s first generation product, BREVAGen®. BREVAGenplus assesses both clinical risk factors and genetic markers known to be associated with sporadic, or non-hereditary, breast cancer to determine a woman’s five-year and lifetime risk of developing the disease. The test is designed to facilitate better informed decisions about breast cancer screening and preventive treatment plans for Caucasian, Hispanic and African-American women, age 35 years or above, who have not had breast cancer, lobular carcinoma in situ (LCIS) or ductal carcinoma in situ (DCIS), and have one or more risk factors for developing breast cancer. To view the Multimedia News Release, go to http://www.multivu.com/players/English/7337351-phenogen-sciences-introduces-brevagenplus-breast-cancer-risk-assessment-test/
Categories // People and Blog  Business 
Added: 1352 days ago by MultiVuVideos
Runtime: 2m12s | Views: 399 | Comments: 1
Not yet rated
 

 

 

Page 1 of 3  |  Go to page    Next» LAST»»



About Us   |   Help  |   Advertise on ClipMoon   |   Terms of Use   |   Privacy Policy   |   Copyright   |   Contact   |   Link us   |   RSS 
Copyright © 2007-2018 ClipMoon.com. All rights reserved.